Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2

• Autors principals: Irving Balbuena-Rebolledo (Autor), Itzia Irene Padilla-Martínez (Autor), Martha Cecilia Rosales-Hernández (Autor), Martiniano Bello (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2021-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Repurposing studies have identified several FDA-approved compounds as potential inhibitors of the intracellular domain of epidermal growth factor receptor 1 (EGFR) and human epidermal receptor 2 (HER2). EGFR and HER2 represent important targets for the design of new drugs against different types of...